FONR FONAR CORP

NEUTRAL Impact: 3/10 8-K
Horizon immediate Filed May 21, 2026 Processed 22d 15h ago SEC 0001193125-26-234914
8-K context-dependent: Items 8.01
Latest settled — T+5d ⚠ clustered
FONR ▲ +1.14% at T+5d
NEUTRAL call ✓ call won +1.14% · α vs SPY -0.52% · entry $18.90 → $19.11
Next anchor: T+20d in 9d
Latest observation: T+8 +0.53% FF3 residual α
Entry anchored
May 21, 2026
via day open
T+1d
+0.08%
call +0.08% · α -0.51%
$18.91
settled 22d ago
T+5d
+1.14%
call +1.14% · α -0.52%
$19.11
settled 15d ago
T+20d
call — · α —
in 9d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

FONAR filed supplemental disclosures to its definitive proxy statement in connection with a pending going-private merger with an entity controlled by its CEO. The supplements address stockholder litigation alleging inadequate disclosures and include corrected background details and fairness opinion figures. The special stockholder vote is scheduled for May 28, 2026.

Actionable Insight

Monitor the outcome of the May 28 special meeting. If the merger is approved, shares will be cashed out at the merger price (not disclosed in this filing); if it fails, the stock could revert to pre-announcement levels.

Key Facts

  • Special stockholder meeting to vote on going-private merger is May 28, 2026.
  • Supplemental disclosures added in response to demand letters and draft complaints from purported stockholders.
  • Marshall & Stevens estimated liquidation value of $14.63 per share in a fairness analysis.
  • Company states no post-signing negotiations regarding officer/director employment arrangements.
  • Transaction is a management buyout led by CEO/Chairman Timothy Damadian.

Financial Impact

No new financial figures; existing merger consideration unchanged by this filing.

Risk Factors

  • Stockholder litigation could delay or block the merger despite the supplemental disclosures.
  • Management buyout may face opposition from minority shareholders, creating uncertainty around deal completion.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-234914
Document: 0001193125-26-234914-index-headers.html0001193125-26-234914
Document: 0001193125-26-234914-index.html0001193125-26-234914
Document: 0001193125-26-234914.txt0001193125-26-234914
5 reports for FONR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FONR — sortable, filterable
Type Now
Jun 3, 2026
9d ago
8-K
NEUTRAL ★ 7/10
$19.09 awaiting T+5awaiting T+5
May 21, 2026
22d ago
DEFA14A
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%
May 21, 2026
22d ago
8-K
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%
May 12, 2026
4w ago
DEFA14A
BEARISH ★ 7/10
$18.86 $18.86· 0.00%▼ −1.16%
May 12, 2026
4w ago
8-K
BEARISH ★ 6/10
$18.86 $18.86· 0.00%▼ −1.16%
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (48h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access